-
Schistosomiasis drug discovery: what rapamycin did here
Schistosomiasis drug discovery runs on a single molecule. Outside a host, rapamycin kills juvenile and adult Schistosoma mansoni at low micromolar concentrations, and adults are roughly 3.2 times more sensitive. Praziquantel remains the only drug in routine use, and it covers immature worms poorly, which is why autophagy genes are being mapped as a target class. Why schistosomiasis drug discovery rests on a single drug Schistosomiasis is a neglected disease caused by blood flukes of the genus Schistosoma. Transmission has been reported in 79 endemic territories, prevalence runs as high as 23.2 percent in some endemic settings, and the burden is not small: 1.7 million disability-adjusted life years were recorded…
-
How Everyday Local Travel Keeps Schistosomiasis Transmission Alive Near Lake Victoria
Schistosomiasis, or bilharzia, is one of the most widespread parasitic diseases on earth. It sickens hundreds of millions of people, most of them in sub-Saharan Africa. For years the global health world has pushed hard against it, and in plenty of places the push has worked. Infection rates fell. Communities that once carried heavy disease burdens now clear the World Health Organization’s bar for “elimination as a public health problem.” Clearing that bar is not the same as killing the parasite off. A growing pile of evidence shows that in some communities the infection keeps humming along even after the numbers look fine on paper, and then it comes back.…
-
Dog Dewormer Showdown: What a Remote-Community Trial Reveals About Hookworm and Flea Control
Most dog owners handle parasites without thinking about it. You buy a tablet, hide it in a treat, done. In remote tropical communities where the nearest vet is hours or days away, it is not that simple, and the consequences run deeper than a sick dog. A field trial published last year asked a plain question: when community members run the treatment themselves, which programs actually work? The answer matters well beyond one stretch of northern Australia. Anyone managing parasites in free-roaming dogs, on an island, in a village, or in an under-resourced shelter, can learn something here. Why this is a public health problem, not just a dog problem…
-
Synriam and Praziquantel: A New Combination Therapy for Schistosomiasis
The Persistent Challenge of Schistosomiasis Schistosomiasis remains one of the most neglected tropical diseases worldwide, affecting hundreds of millions of people across Africa, Asia, and South America. Despite decades of control efforts, this parasitic infection continues to burden resource-limited communities where access to clean water and adequate sanitation remains scarce. For years, praziquantel has stood as the primary weapon against schistosomiasis. It works, it is relatively safe, and it does not break the bank. But the drug has its problems. Most notably, praziquantel shows reduced efficacy against juvenile worms, particularly those in the early stages of development. This creates a frustrating gap: infected individuals carry immature parasites that survive standard…
-
Praziquantel
Welcome to the ultimate resource for Praziquantel CAS No. 55268-74-1, a highly effective anthelmintic trusted worldwide for its efficacy in treating parasitic infections. Manufactured by Henan Haitian Biotechnology Co., Ltd., a leader in pharmaceutical innovation, this product stands out for its quality, reliability, and compliance with global standards. Whether you’re a researcher, healthcare professional, or distributor, discover why our Praziquantel is the top choice for combating schistosomiasis and other parasitic diseases. What is Praziquantel CAS No. 55268-74-1? Name: Praziquantel Synonyms: 2-Cyclohexyl-carbonyl-1,3,4,6,7,11b-hexahydro-2H-pyrazine(2,1-a)isoquinoline-4-one Molecular Formula C19H24N2O2 Molecular Weight 312.41 CAS Registry Number 55268-74-1 EINECS 259-559-6 Praziquantel is used to treat infections caused by schistosoma worms, which enter the body through skin that…







